Semaglutide improves 1-year survival and liver outcomes in nearly 20,000 MASLD patients in real-world analysis | Research

The takeaway

In 38,224 propensity-matched MASLD patients, semaglutide-treated patients showed significantly improved 1-year survival, cardiovascular outcomes, and liver-related complications including reduced advanced liver disease despite starting with higher BMI.

Improved survival in ~20,000 patients
Largest real-world MASLD study shows semaglutide significantly improves 1-year survival and liver outcomes despite patients starting with higher BMI

What the researchers found

38,224 matched patients (19,112 each). BMI reduction ~1 point. Significantly improved: 1-year survival, cardiovascular parameters, liver-related outcomes, advanced liver disease markers, synthetic function. 34 matching variables. TriNetX platform.

Why it matters

This is the largest real-world MASLD semaglutide study to date. Showing improved survival and reduced advanced liver disease in nearly 20,000 treated patients provides compelling evidence for semaglutide as a disease-modifying MASLD therapy.

How the study worked

Propensity score-matched cohort from TriNetX (135M patients, 112 healthcare organizations). 34-variable matching. MASLD by ICD9. Outcomes: survival, biochemical, metabolic, cardiovascular, liver-specific.

What this study cannot tell us

Observational. Short follow-up (1 year). Semaglutide group had higher baseline BMI (potential selection bias). TriNetX data quality varies across sites.

How to read the evidence

Large propensity-matched cohort from a 135M-patient database. Strong real-world evidence.

When this study was published

Published in 2025.

The bigger picture

MASLD affects 30% of the global population. Demonstrating that semaglutide improves survival and prevents advanced liver disease in this large real-world cohort supports its use as a cornerstone MASLD therapy.

Questions still open

Does the survival benefit persist beyond 1 year?
Is the liver benefit from weight loss, anti-inflammatory effects, or both?
Should semaglutide be first-line for all MASLD patients?

Common questions

Does semaglutide help fatty liver disease?

This study of nearly 20,000 treated patients—the largest of its kind—found semaglutide significantly improved survival, cardiovascular health, and liver outcomes in fatty liver disease patients over 1 year. It also reduced markers of advanced liver disease, suggesting it can prevent liver damage progression.

Should all fatty liver patients take semaglutide?

This study provides strong support for semaglutide in MASLD, but treatment decisions should consider individual factors including cost, other medications, and severity of liver disease. The benefits were consistent despite semaglutide patients starting with higher BMI, suggesting broad applicability.

Read the original research

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.

Pharmaceuticals (Basel, Switzerland), 18(7)

View on PubMed ↗Publisher’s paper ↗

Citation

Suki, Mohamad; Amer, Johnny; Milgrom, Yael; Massarwa, Muhammad; Hazou, Wadi; Tiram, Yariv; Perzon, Ofer; Sharif, Yousra; Sackran, Joseph; Alon, Revital; Lourie, Nachum Emil Eliezer; Raz, Itamar; Imam, Ashraf; Khalaileh, Abed; Safadi, Rifaat. (2025). Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.. Pharmaceuticals (Basel, Switzerland), 18(7). https://doi.org/10.3390/ph18071075